The study's authors aimed to learn more about an area where clinical evidence was lacking: statin therapy for stroke patients 80 years old and older. 

Researchers explained that their findings were different from previous studies because they took a wide variety of factors, including underlying health conditions, into account. 

Researchers turned to accelerometers, lightweight motion sensors that can be attached to a user’s wrist, to investigate this topic. 

Vegetarian diets must still contain heart-healthy choices, the researchers wrote—simply doing away with meat is not enough to turn around your health. 

These trends were not observed among male COVID-19 patients.

The study, published in JAMA Network Open, included data from more than 64,000 COVID-19 patients.

The authors explored data from more than 800 patients with coronary heart disease, sharing their findings in Plos Medicine.

Treatment with empagliflozin for six months was associated with several key improvements. This suggests that, yes, SGLT2 inhibitors can be recommended for HFrEF patients who don't have diabetes. 

“These observations support rigorous adherence to COVID-19 prevention strategies in obese individuals of all ages,” the researchers wrote. 

These findings are especially important, the authors wrote, because they suggest there may be a new way to personalize patient care. 

The analysis focused on more than 241,000 patients with diabetes.

Underweight patients, meanwhile, had the highest mortality rates following hospitalization for ACS.